
Gilead Sciences, Inc.: shareholders and insiders
Price
$168.98
November 18, 2026Market cap $210B
What Ploutos Investor adds for Gilead Sciences
Part of Ploutos Investor, €9.99 a month
- The full history: 17 fiscal years, from 2009
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Insiders and their shares
Purchases and sales by officers and directors from Nov 19, 2025 to Nov 17, 2026, from their own Form 4 filings.
Bought on the market
–
nobody
Sold on the market
$109M
7 people
From Nov 19, 2025 to Nov 19, 2026, the days the chart shows. Change its range and the figures follow.
How the sales were made, as a share of their value
- Under a set plan99%
- The rest1%
By year
Insiders' open-market purchases (up) and sales (down), by value, since Nov 19, 2025, on a log scale: each gridline is ten times the last. From the SEC's quarterly data sets of Form 4 filings.
2026·no buys·sold $104M by 7 people
- 2025: no buys, sold $4.6M by 5 people
- 2026: no buys, sold $104M by 7 people
- Nov 16, 2026Johanna MercierChief Comm & Corp Aff OfficerKind10b5-1
- Nov 16, 2026Johanna MercierChief Comm & Corp Aff OfficerKind10b5-1
- Nov 16, 2026Johanna MercierChief Comm & Corp Aff OfficerKind10b5-1
- Nov 16, 2026Johanna MercierChief Comm & Corp Aff OfficerKind10b5-1
- Nov 16, 2026Andrew D DickinsonChief Financial OfficerKind10b5-1
- Nov 12, 2026Kelly A. KramerDirectorKind10b5-1
- Nov 12, 2026Kelly A. KramerDirectorKind10b5-1
- Nov 12, 2026Kelly A. KramerDirectorKind10b5-1
- Nov 12, 2026Kelly A. KramerDirectorKind10b5-1
- Nov 12, 2026Kelly A. KramerDirectorKind10b5-1
- Nov 6, 2026Wettan Keeley M CainEVP Gen Counsel, Legal & CompKind10b5-1
- Nov 5, 2026Daniel Patrick O'DayChairman & CEOKind10b5-1
- Nov 5, 2026Daniel Patrick O'DayChairman & CEOKind10b5-1
- Nov 4, 2026Daniel Patrick O'DayChairman & CEOKind10b5-1
- Nov 4, 2026Daniel Patrick O'DayChairman & CEOKind10b5-1
- Nov 2, 2026Daniel Patrick O'DayChairman & CEOKind10b5-1
- Nov 2, 2026Daniel Patrick O'DayChairman & CEOKind10b5-1
- Nov 2, 2026Daniel Patrick O'DayChairman & CEOKind10b5-1
- Nov 2, 2026Daniel Patrick O'DayChairman & CEOKind10b5-1
- Nov 2, 2026Daniel Patrick O'DayChairman & CEOKind10b5-1
- Oct 30, 2026Daniel Patrick O'DayChairman & CEOKind10b5-1
- Oct 30, 2026Daniel Patrick O'DayChairman & CEOKind10b5-1
- Oct 15, 2026Andrew D DickinsonChief Financial OfficerKind10b5-1
- Oct 15, 2026Johanna MercierChief Comm & Corp Aff OfficerKind10b5-1
- Oct 1, 2026Daniel Patrick O'DayChairman & CEOKind10b5-1
| Date | Person | Kind | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Nov 16, 2026 | Johanna MercierChief Comm & Corp Aff Officer | 10b5-1 | 25.0K | $72.34 | $1.8M | Form 4 |
| Nov 16, 2026 | Johanna MercierChief Comm & Corp Aff Officer | 10b5-1 | 13.9K | $169.97 | $2.4M | Form 4 |
| Nov 16, 2026 | Johanna MercierChief Comm & Corp Aff Officer | 10b5-1 | 13.2K | $171.09 | $2.3M | Form 4 |
| Nov 16, 2026 | Johanna MercierChief Comm & Corp Aff Officer | 10b5-1 | 900 | $171.69 | $154.5K | Form 4 |
| Nov 16, 2026 | Andrew D DickinsonChief Financial Officer | 10b5-1 | 3,000 | $171.47 | $514.4K | Form 4 |
| Nov 12, 2026 | Kelly A. KramerDirector | 10b5-1 | 10.4K | $66.92 | $694.4K | Form 4 |
| Nov 12, 2026 | Kelly A. KramerDirector | 10b5-1 | 1,676 | $168.23 | $281.9K | Form 4 |
| Nov 12, 2026 | Kelly A. KramerDirector | 10b5-1 | 3,800 | $169.44 | $643.9K | Form 4 |
| Nov 12, 2026 | Kelly A. KramerDirector | 10b5-1 | 4,700 | $170.49 | $801.3K | Form 4 |
| Nov 12, 2026 | Kelly A. KramerDirector | 10b5-1 | 200 | $171.44 | $34.3K | Form 4 |
| Nov 6, 2026 | Wettan Keeley M CainEVP Gen Counsel, Legal & Comp | 10b5-1 | 3,399 | $164.11 | $557.8K | Form 4 |
| Nov 5, 2026 | Daniel Patrick O'DayChairman & CEO | 10b5-1 | 9,810 | $72.34 | $709.7K | Form 4 |
| Nov 5, 2026 | Daniel Patrick O'DayChairman & CEO | 10b5-1 | 9,810 | $175.17 | $1.7M | Form 4 |
| Nov 4, 2026 | Daniel Patrick O'DayChairman & CEO | 10b5-1 | 102.6K | $72.34 | $7.4M | Form 4 |
| Nov 4, 2026 | Daniel Patrick O'DayChairman & CEO | 10b5-1 | 102.6K | $175.16 | $18M | Form 4 |
| Nov 2, 2026 | Daniel Patrick O'DayChairman & CEO | 10b5-1 | 1,600 | $167.40 | $267.8K | Form 4 |
| Nov 2, 2026 | Daniel Patrick O'DayChairman & CEO | 10b5-1 | 1,700 | $168.10 | $285.8K | Form 4 |
| Nov 2, 2026 | Daniel Patrick O'DayChairman & CEO | 10b5-1 | 1,904 | $169.27 | $322.3K | Form 4 |
| Nov 2, 2026 | Daniel Patrick O'DayChairman & CEO | 10b5-1 | 7,796 | $170.35 | $1.3M | Form 4 |
| Nov 2, 2026 | Daniel Patrick O'DayChairman & CEO | 10b5-1 | 2,000 | $171.06 | $342.1K | Form 4 |
| Oct 30, 2026 | Daniel Patrick O'DayChairman & CEO | 10b5-1 | 15.9K | $72.34 | $1.1M | Form 4 |
| Oct 30, 2026 | Daniel Patrick O'DayChairman & CEO | 10b5-1 | 15.9K | $175.25 | $2.8M | Form 4 |
| Oct 15, 2026 | Andrew D DickinsonChief Financial Officer | 10b5-1 | 3,000 | $156.22 | $468.7K | Form 4 |
| Oct 15, 2026 | Johanna MercierChief Comm & Corp Aff Officer | 10b5-1 | 3,000 | $156.22 | $468.7K | Form 4 |
| Oct 1, 2026 | Daniel Patrick O'DayChairman & CEO | 10b5-1 | 12.0K | $147.72 | $1.8M | Form 4 |
From the Form 4s insiders file with the SEC within two business days of each trade. Before May 27, 2026 the table lists open-market purchases and sales only (no grants, option exercises or tax withholding), from the SEC's quarterly data sets. The 10b5-1 mark comes from the form's own box (since April 2023) or from a footnote of the filing that names the plan, where there is one.
Insiders and their shares
Every buy and sale by GILD's officers and directors from 2006 up to November 18, 2025, 20 more calendar years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 3 years.
and 15 more, back to 2006
Major holders (over 5%)
Whoever comes to own more than 5% of a class of shares reports it to the SEC on Schedule 13D or 13G. Here is each holder's latest filing.
- BlackRock, Inc.Share of class8.20%
- Vanguard Capital ManagementShare of class7.51%
- FMRwith 1 more personShare of class5.30%
| Holder | Kind of stake | Share of class | Shares | Filed | Filing |
|---|---|---|---|---|---|
| BlackRock, Inc. | 8.20% | 102M | Apr 24, 2025 | 13G/A | |
| Vanguard Capital Management | 7.51% | 93.33M | Apr 29, 2026 | 13G | |
| FMRwith 1 more person | 5.30% | 65.54M | Feb 5, 2026 | 13G |
Fell to 5% or less (2)
Holders whose latest filing says they hold 5% or less. After it they need not file again, so what they hold today is not known.
From the Schedule 13D and 13G filed with the SEC since Dec 18, 2024, when they became structured data. A holder who has filed nothing since then is not shown here. A 13D is updated within two business days of any material change, a 13G up to 45 days after the quarter of the change, so the shares are those of the filing. The large managers also appear in the 13Fs.
Well-known managers
Which of the about 30 investment managers we track held the shares at the quarter end, and what they changed from the quarter before.
- Renaissance TechnologiesIn the quarter-7.3%
- Point72 (Cohen)In the quarter
- Bridgewater (Dalio)In the quarter+10%
- Millennium Mgmt (Englander)In the quarter+12%
- D.E. ShawIn the quarter-17%
- Citadel Advisors (Griffin)In the quarter-50%
- AQR CapitalIn the quarter+217%
| Manager | Shares | In the quarter | Value | % of their portfolio |
|---|---|---|---|---|
| Renaissance Technologies | 2.05M | -7.3% | $306M | 0.42% |
| Point72 (Cohen) | – | – | 0.28% | |
| Bridgewater (Dalio) | 321.4K | +10% | $48M | 0.21% |
| Millennium Mgmt (Englander) | 1.63M | +12% | $243M | 0.18% |
| D.E. Shaw | 1.91M | -17% | $285M | 0.18% |
| Citadel Advisors (Griffin) | 1.73M | -50% | $258M | 0.14% |
| AQR Capital | 2.20M | +217% | $328M | 0.10% |
From the 13Fs managers file with the SEC up to 45 days after each quarter end. They show only long positions on that day, not short sales or what has changed since. No recent 13F: Pershing Square (Ackman), Scion (Burry).
Short interest
How many of the company's shares have been sold borrowed and not yet bought back, twice a month.
On Oct 15, 2026, 1.63% of its shares outstanding were held short, -7.1% since the report before.
- Shares held short
- 20.27M
- 1.63%
- Since the report before21.83M on Sep 30, 2026
- -7.1%
- 3.7
- 5.45M
- More days to cover thanof 4,578 US-listed companies with enough volume
- 44%
- Report date
- Oct 15, 2026
- Shares held short
- Oct 31, 2023: Shares held short 19.50M
- Nov 15, 2023: Shares held short 18.13M
- Nov 30, 2023: Shares held short 17.42M
- Dec 15, 2023: Shares held short 18.50M
- Dec 29, 2023: Shares held short 17.04M
- Jan 12, 2024: Shares held short 17.14M
- Jan 31, 2024: Shares held short 15.66M
- Feb 15, 2024: Shares held short 19.88M
- Feb 29, 2024: Shares held short 19.67M
- Mar 15, 2024: Shares held short 19.25M
- Mar 28, 2024: Shares held short 22.57M
- Apr 15, 2024: Shares held short 21.18M
- Apr 30, 2024: Shares held short 21.16M
- May 15, 2024: Shares held short 21.70M
- May 31, 2024: Shares held short 25.43M
- Jun 14, 2024: Shares held short 18.81M
- Jun 28, 2024: Shares held short 23.00M
- Jul 15, 2024: Shares held short 21.25M
- Jul 31, 2024: Shares held short 17.84M
- Aug 15, 2024: Shares held short 16.77M
- Aug 30, 2024: Shares held short 19.80M
- Sep 13, 2024: Shares held short 19.95M
- Sep 30, 2024: Shares held short 17.74M
- Oct 15, 2024: Shares held short 16.48M
- Oct 31, 2024: Shares held short 17.74M
- Nov 15, 2024: Shares held short 18.06M
- Nov 29, 2024: Shares held short 23.41M
- Dec 13, 2024: Shares held short 21.98M
- Dec 31, 2024: Shares held short 25.66M
- Jan 15, 2025: Shares held short 25.17M
- Jan 31, 2025: Shares held short 22.93M
- Feb 14, 2025: Shares held short 21.16M
- Feb 28, 2025: Shares held short 22.58M
- Mar 14, 2025: Shares held short 22.34M
- Mar 31, 2025: Shares held short 21.39M
- Apr 15, 2025: Shares held short 20.08M
- Apr 30, 2025: Shares held short 23.57M
- May 15, 2025: Shares held short 24.68M
- May 30, 2025: Shares held short 20.94M
- Jun 13, 2025: Shares held short 22.99M
- Jun 30, 2025: Shares held short 20.99M
- Jul 15, 2025: Shares held short 22.54M
- Jul 31, 2025: Shares held short 19.99M
- Aug 15, 2025: Shares held short 18.23M
- Aug 29, 2025: Shares held short 17.56M
- Sep 15, 2025: Shares held short 18.25M
- Sep 30, 2025: Shares held short 18.04M
- Oct 15, 2025: Shares held short 15.80M
- Oct 31, 2025: Shares held short 17.98M
- Nov 14, 2025: Shares held short 17.01M
- Nov 28, 2025: Shares held short 18.48M
- Dec 15, 2025: Shares held short 21.65M
- Dec 31, 2025: Shares held short 23.15M
- Jan 15, 2026: Shares held short 22.97M
- Jan 30, 2026: Shares held short 23.68M
- Feb 13, 2026: Shares held short 21.89M
- Feb 27, 2026: Shares held short 18.45M
- Mar 13, 2026: Shares held short 19.99M
- Mar 31, 2026: Shares held short 21.52M
- Apr 15, 2026: Shares held short 22.75M
- Apr 30, 2026: Shares held short 23.05M
- May 15, 2026: Shares held short 23.14M
- May 29, 2026: Shares held short 25.73M
- Jun 15, 2026: Shares held short 23.86M
- Jun 30, 2026: Shares held short 25.48M
- Jul 15, 2026: Shares held short 25.26M
- Jul 31, 2026: Shares held short 24.39M
- Aug 14, 2026: Shares held short 23.18M
- Aug 31, 2026: Shares held short 23.01M
- Sep 15, 2026: Shares held short 18.30M
- Sep 30, 2026: Shares held short 21.83M
- Oct 15, 2026: Shares held short 20.27M
As brokers report them to the regulator twice a month, mid-month and at month end, published about eight business days later. A short position is shares sold borrowed and not yet bought back. The share count is the one the company's market value is figured on, from its filings. Days to cover is the shares held short over the average daily volume of the weeks between two reports.
Short sales in daily trading42.7% of the shares in the last 14 sessions' reported trades were short sales.
In the last 14 sessions, 42.7% of the shares in the reported trades were short sales, against 47.6% in the 14 before.
- Last 14 sessionsOct 30, 2026 – Nov 18, 2026
- 42.7%
- The 14 beforeOct 12, 2026 – Oct 29, 2026
- 47.6%
- Change
- -4.9 pts
- Short sales a dayon average, of 2.20M shares
- 939.0K
- More than atof 3,656 US-listed companies, same days
- 26%
- Median of alleight in ten from 34.4% to 63.7%
- 50.3%
- Short sales
- Oct 12, 2026: Short sales 45.1%
- Oct 13, 2026: Short sales 36.8%
- Oct 14, 2026: Short sales 45.1%
- Oct 15, 2026: Short sales 49.5%
- Oct 16, 2026: Short sales 39.2%
- Oct 19, 2026: Short sales 45.5%
- Oct 20, 2026: Short sales 43.4%
- Oct 21, 2026: Short sales 47%
- Oct 22, 2026: Short sales 38.6%
- Oct 23, 2026: Short sales 51.7%
- Oct 26, 2026: Short sales 61.1%
- Oct 27, 2026: Short sales 50.5%
- Oct 28, 2026: Short sales 52.9%
- Oct 29, 2026: Short sales 54.2%
- Oct 30, 2026: Short sales 47.1%
- Nov 2, 2026: Short sales 41.2%
- Nov 3, 2026: Short sales 38.7%
- Nov 4, 2026: Short sales 39.6%
- Nov 5, 2026: Short sales 35.3%
- Nov 6, 2026: Short sales 42.4%
- Nov 9, 2026: Short sales 52%
- Nov 10, 2026: Short sales 53.4%
- Nov 11, 2026: Short sales 38.4%
- Nov 12, 2026: Short sales 46.2%
- Nov 13, 2026: Short sales 39.8%
- Nov 16, 2026: Short sales 38.1%
- Nov 17, 2026: Short sales 45.2%
- Nov 18, 2026: Short sales 50.8%
This is not the number of shares sold short today: it measures short sales within each day's trading, and only trades made off the exchanges. Much of it is market makers, who sell shares they do not have to fill buyers' orders and cover soon after, so for a heavily traded stock the share is often around half.
What the insiders hold
The shares each insider reports holding after their latest trade (Form 4), for those who traded on the market in the last three years.
- Daniel Patrick O'DayChairman & CEODirectly551.7K
- Andrew D DickinsonChief Financial OfficerDirectly158.1K
- Johanna MercierChief Comm & Corp Aff OfficerDirectly110.7K
- Merdad ParseyChief Medical OfficerDirectly99.6K
- Deborah H TelmanEVP, Corporate Affairs & GCDirectly43.7K
- Dietmar BergerChief Medical OfficerDirectly19.5K
- Anthony WeltersDirectorDirectly17.5K
- Jeffrey BluestoneDirectorDirectly10.1K
- Wettan Keeley M CainEVP Gen Counsel, Legal & CompDirectly5,360
- Erin BurkhartSVP, ControllershipDirectly1,455
- Kelly A. KramerDirectorDirectly1,339
| Person | Directly | Indirectly | After the trade of | Filing |
|---|---|---|---|---|
| Daniel Patrick O'DayChairman & CEO | 551.7K | – | Nov 5, 2026 | Form 4 |
| Andrew D DickinsonChief Financial Officer | 158.1K | – | Nov 16, 2026 | Form 4 |
| Johanna MercierChief Comm & Corp Aff Officer | 110.7K | – | Nov 16, 2026 | Form 4 |
| Merdad ParseyChief Medical Officer | 99.6K | – | Nov 27, 2024 | Form 4 |
| Deborah H TelmanEVP, Corporate Affairs & GC | 43.7K | – | Nov 12, 2025 | Form 4 |
| Dietmar BergerChief Medical Officer | 19.5K | – | Sep 10, 2026 | Form 4 |
| Anthony WeltersDirector | 17.5K | – | Aug 26, 2026 | Form 4 |
| Jeffrey BluestoneDirector | 10.1K | – | Aug 20, 2026 | Form 4 |
| Wettan Keeley M CainEVP Gen Counsel, Legal & Comp | 5,360 | – | Nov 6, 2026 | Form 4 |
| Erin BurkhartSVP, Controllership | 1,455 | – | Sep 22, 2026 | Form 4 |
| Kelly A. KramerDirector | 1,339 | – | Nov 12, 2026 | Form 4 |
A lower bound: it counts only the 11 officers and directors with a market trade since Nov 20, 2023. Anyone who neither bought nor sold since is not here, whatever they hold. The share is against the share count on the latest 10-K's cover.
10b5-1 trading plans
Since 2023 every 10-Q and 10-K says which insiders adopted or ended a trading plan (Rule 10b5-1) in the quarter: when, for how many shares, until when. A plan explains the sales that follow months before they show up on Form 4.
- Kelly KramerBoard of DirectorsWhat happenedAdoptedAug 13, 2026Shares19.9K
- Andrew DickinsonChief Financial OfficerWhat happenedAdoptedAug 7, 2026Shares272.6K
- Keeley Cain WettanExecutive Vice President and General Counsel, Legal and ComplianceWhat happenedAdoptedAug 7, 2026Shares–
- Anthony WeltersBoard of DirectorsWhat happenedAdoptedMay 27, 2026Shares18.0K
- Jeffrey BluestoneBoard of DirectorsWhat happenedAdoptedMay 20, 2026Shares10.0K
- Daniel P. O’DayChief Executive OfficerWhat happenedAdoptedFeb 25, 2026Shares748.0K
- Kelly Kramermember of our Board of DirectorsWhat happenedAdoptedAug 27, 2025Shares5,611
- Deborah TelmanExecutive Vice President of Corporate AffairsWhat happenedAdoptedAug 13, 2025Shares91.9K
- Daniel P. O’DayChief Executive OfficerWhat happenedAdoptedFeb 28, 2025Shares351.3K
- Johanna MercierChief Commercial OfficerWhat happenedAdoptedFeb 20, 2025Shares266.0K
| Person | What happened | Until | Shares | Filing |
|---|---|---|---|---|
| Kelly KramerBoard of Directors | AdoptedAug 13, 2026 | Aug 10, 2027 | 19.9K | 10-Q |
| Andrew DickinsonChief Financial Officer | AdoptedAug 7, 2026 | May 31, 2028 | 272.6K | 10-Q |
| Keeley Cain WettanExecutive Vice President and General Counsel, Legal and Compliance | AdoptedAug 7, 2026 | Sep 30, 2027 | – | 10-Q |
| Anthony WeltersBoard of Directors | AdoptedMay 27, 2026 | Dec 31, 2026 | 18.0K | 10-Q |
| Jeffrey BluestoneBoard of Directors | AdoptedMay 20, 2026 | Jan 31, 2027 | 10.0K | 10-Q |
| Daniel P. O’DayChief Executive Officer | AdoptedFeb 25, 2026 | May 29, 2027 | 748.0K | 10-Q |
| Kelly Kramermember of our Board of Directors | AdoptedAug 27, 2025 | Aug 19, 2026 | 5,611 | 10-Q |
| Deborah TelmanExecutive Vice President of Corporate Affairs | AdoptedAug 13, 2025 | Nov 16, 2026 | 91.9K | 10-Q |
| Daniel P. O’DayChief Executive Officer | AdoptedFeb 28, 2025 | May 29, 2026 | 351.3K | 10-Q |
| Johanna MercierChief Commercial Officer | AdoptedFeb 20, 2025 | Feb 19, 2027 | 266.0K | 10-Q |
As the company states them in Item 9B of the 10-K and Part II, Item 5 of the 10-Q, with structured data. A plan allows sales on preset dates and prices. It does not say whether all of them will be executed.
Executive pay
From the Pay versus Performance table every company puts in its proxy statement since 2023: what the chief executive was paid, what was actually paid once the shares vest at year-end values, and how the stock did against the peer group the company itself picked.
$28M
Actually paid: $63M
$9.2M
Actually paid: $13M
$255
Peers: $125
Net Product Sales
$28.9B
From the proxy statement (DEF 14A) of Mar 20, 2026, as filed with the SEC with structured data. Pay in dollars. The company picks its own peer group and measure. DEF 14A
Share repurchases
How many of its own shares the company bought each quarter, at what average price, for how much, and what remains of the program its board authorized, from the table it puts in every 10-Q and 10-K.
- Jun 30, 202610-QAmount$416M
- Dec 31, 202510-KAmount$293M
- Sep 30, 202510-QAmount$573M
- Jun 30, 202510-QAmount$587M
- Mar 31, 202510-QAmount$906M
- Dec 31, 202410-KAmount$397M
- Sep 30, 202410-QAmount$382M
- Jun 30, 202410-QAmount$133M
| Quarter | Shares | Average price | Amount | Left in the program | Filing |
|---|---|---|---|---|---|
| Jun 30, 202610-Q | 3.19M | $130.58 | $416M | $6.0B | 10-Q |
| Dec 31, 202510-K | 2.46M | $119.17 | $293M | $6.8B | 10-K |
| Sep 30, 202510-Q | 5.01M | $114.25 | $573M | $7.0B | 10-Q |
| Jun 30, 202510-Q | 5.53M | $106.10 | $587M | $1.5B | 10-Q |
| Mar 31, 202510-Q | 8.70M | $104.16 | $906M | $2.0B | 10-Q |
| Dec 31, 202410-K | 4.34M | $91.58 | $397M | $2.7B | 10-K |
| Sep 30, 202410-Q | 5.01M | $76.32 | $382M | $3.1B | 10-Q |
| Jun 30, 202410-Q | 2.01M | $66.38 | $133M | $3.4B | 10-Q |
From the "Issuer Purchases of Equity Securities" table of the 10-Qs and 10-Ks, read without a model. Only the quarters whose shares times average price agree with the cash the company says it paid for repurchases in its cash-flow statement are shown. The shares include those withheld for officers' taxes. A quarter with an accelerated repurchase shows the table's shares and the cash paid, without an average price. 2 filing(s) not shown, as the table was not read or did not agree with the cash.
The shareholders' vote on pay
The advisory say-on-pay vote at each annual meeting, as the company states it in the 8-K it files after the meeting: how many voted for and against the executives' pay. 90% is the norm. Under 70% proxy advisers expect the board to respond the next year.
- 2026May 4, 2026For92.5%
- 2025May 8, 2025For91.2%
- 2024May 9, 2024For92.2%
- 2023May 5, 2023For92.0%
- 2022May 5, 2022For92.2%
- 2021May 14, 2021For87.1%
| Year | For | Votes for | Votes against | Abstentions | Broker non-votes | Filing |
|---|---|---|---|---|---|---|
| 2026May 4, 2026 | 92.5% | 954M | 77.50M | 3.34M | 95.01M | 8-K |
| 2025May 8, 2025 | 91.2% | 930M | 89.35M | 2.42M | 99.96M | 8-K |
| 2024May 9, 2024 | 92.2% | 929M | 78.65M | 1.81M | 106M | 8-K |
| 2023May 5, 2023 | 92.0% | 919M | 79.50M | 3.26M | 110M | 8-K |
| 2022May 5, 2022 | 92.2% | 876M | 74.35M | 2.18M | 131M | 8-K |
| 2021May 14, 2021 | 87.1% | 812M | 120M | 2.30M | 129M | 8-K |
From the 8-K (item 5.07) the company files after each annual meeting since 2021, read from the filing's text without a model. A company that votes every three years has empty years. The vote is advisory: the board is not bound by it.
The ETFs that hold it
Which of the 345 US equity ETFs we track hold the stock, and at what weight, from the funds' N-PORT filings.
- IBBiShares Biotechnology ETFWeight in the fund6.84%
- XLVState Street(R) Health Care Select Sector SPDR(R) ETFWeight in the fund2.73%
- IYHiShares U.S. Healthcare ETFWeight in the fund2.66%
- VHTVanguard Health Care Index FundWeight in the fund2.52%
- IXJiShares Global Healthcare ETFWeight in the fund2.04%
- COWZPacer US Cash Cows 100 ETFWeight in the fund1.93%
- FTCSFirst Trust Capital Strength ETFWeight in the fund1.85%
- DGRWWisdomTree U.S. Quality Dividend Growth FundWeight in the fund1.25%
- DUHPDimensional US High Profitability ETFWeight in the fund1.10%
- XBIState Street(R) SPDR(R) S&P(R) Biotech ETFWeight in the fund0.96%
78 of the 345 ETFs we track, not of every ETF on the market. The ten largest weights. Positions as each fund filed them in its latest N-PORT.
Institutional investors by quarter
Every manager that reports positions to the SEC (Form 13F), quarter by quarter: how many hold the stock, how many shares and dollars between them, and who entered, left, added or trimmed during the quarter.
- Managers
- Q3 2025: Managers 2,036
- Q4 2025: Managers 2,223
- Q1 2026: Managers 2,329
- Q2 2026: Managers 2,278
Institutional investors by quarter
The fund managers holding GILD, quarter by quarter, from Q1 2013 to Q2 2025, 50 more quarters
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 12 quarters.
Q2 2026: 2,278 managers held 1.11B shares, worth $141B. During the quarter 151 opened a position, 202 closed one, 925 added and 841 trimmed.
The largest holders, Q2 2026
- BlackRockIn the quarter+2.4%
- Vanguard Capital ManagementIn the quarter+0.5%
- FMRIn the quarter-7.0%
- State StreetIn the quarter+2.3%
- Capital World InvestorsIn the quarter-0.7%
- InvescoIn the quarter-4.2%
- Vanguard Portfolio ManagementIn the quarter+0.5%
- Geode Capital ManagementIn the quarter+1.1%
- Price T Rowe AssociatesIn the quarter+14%
- Morgan StanleyIn the quarter+3.0%
| Manager | Shares | In the quarter | Value |
|---|---|---|---|
| BlackRock | 122M | +2.4% | $15.4B |
| Vanguard Capital Management | 81.09M | +0.5% | $10.2B |
| FMR | 66.87M | -7.0% | $8.4B |
| State Street | 61.22M | +2.3% | $7.7B |
| Capital World Investors | 40.99M | -0.7% | $5.2B |
| Invesco | 39.82M | -4.2% | $5.0B |
| Vanguard Portfolio Management | 35.32M | +0.5% | $4.5B |
| Geode Capital Management | 30.07M | +1.1% | $3.8B |
| Price T Rowe Associates | 30.00M | +14% | $3.8B |
| Morgan Stanley | 24.00M | +3.0% | $3.0B |
From the SEC's Form 13F data sets, Q3 2025 to Q2 2026: the long positions of every manager with more than $100 million under management, as filed up to 45 days after each quarter end. Short positions and options are not in them. Shares as reported each quarter, not adjusted for splits. The stock is matched by its CUSIP, through the SEC's fails-to-deliver files.
The full analysis
What do Gilead Sciences's filings show?
Who buys and sells is one part of Gilead Sciences's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Have GILD's insiders bought or sold?
From May 27, 2026 to Nov 17, 2026 Gilead Sciences's insiders bought 0 and sold $54M of shares on the market. 100% of the sales were under set 10b5-1 plans.
Which well-known managers hold GILD?
7 of the managers we track held the shares on Sep 30, 2026. The largest position was AQR Capital's, worth $328M.
Is every insider transaction a purchase or a sale?
No. Many are part of their pay: share awards, option exercises and shares the company keeps for the tax. Only code P is a purchase with their own money, and code S a sale on the market.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.